Hosted on MSN

Roche reports Phase 3 data for satralizumab in SatraGO-1, SatraGO-2

Roche (RHHBY) presented at ASPORS meeting primary results of the Phase 3 SatraGO-1 and SatraGO-2 trials — Efficacy and Safety of Satralizumab in Thyroid Eye Disease. The SatraGO-1 study in active TED ...
Nasdaq

Iterum Therapeutics Reports Positive Phase 3 Trial Results for ORLYNVAH™ in Treating Uncomplicated Urinary Tract Infections

Iterum Therapeutics plc announced the publication of results from its Phase 3 clinical trial, REASSURE, in NEJM Evidence, which evaluated the efficacy of oral sulopenem compared to Augmentin® in ...
Fierce Pharma

Neurocrine's Ingrezza fails phase 3 trial for cerebral palsy

Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. | Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to ...
TipRanks on MSN

Merck reports 'positive' results from Phase 3 KEYNOTE-B15 trial

Merck (MRK) announced positive topline results from the Phase 3 KEYNOTE-B15 trial in patients with muscle-invasive bladder cancer who are eligible ...
Seeking Alpha

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Study met primary and secondary endpoints Paridiprubart demonstrated a relative reduction in the risk of death of 25% Treatment provided patients with clinically meaningful improvement in survival and ...
Medscape

Psilocybin Safe, Effective for Treatment-Resistant Depression: Phase 3 Data

A single dose of a synthetic form of psilocybin known as COMP360 (Compass Pathways) is both statistically significant and clinically meaningful in reducing treatment-resistant depression (TRD) in a ...
Business Wire

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

“The positive top-line results at week 6 from the COMP005 trial underscore the innovative potential of psilocybin treatment in mental health care for which Compass Pathways continues to pave the way,” ...
EurekAlert!

Mount Sinai dermatologist reports Phase 3 success for rocatinlimab in moderate-to-severe eczema

New York, NY (November 25, 2025) – An international team of investigators led by Emma Guttman-Yassky, MD, PhD, Waldman Professor and System Chair of the Kimberly and Eric J. Waldman Department of ...
Nasdaq

Rhythm Pharmaceuticals Reports Positive Phase 2 Trial Results for Bivamelagon in Acquired Hypothalamic Obesity with Significant BMI Reductions

Bivamelagon showed significant BMI reductions in hypothalamic obesity patients, prompting Rhythm Pharmaceuticals to seek FDA guidance for Phase 3 trials. Rhythm Pharmaceuticals, Inc. announced ...
The Manila Times

Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®

IXCHIQ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV) Antibody levels remained high after twelve months in both dose groups, ...
WKRG

Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), today announced positive topline data from VESPER-1 and positive data from a planned interim analysis for tolerability of ...
Morningstar

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint ...